Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure

Harvey C. Krasny, Sam H.T. Liao, Paulo De Miranda, Oscar L. Laskin, Andrew Whelton, Paul S. Lietman

Research output: Contribution to journalArticle

Abstract

The pharmacokinetic disposition of acyclovir was studied in six patients with chronic renal failure (CRF) and anuria. At the end of a one-hour intravenous infusion (2.5 mg/kg), the mean peak acyclovir plasma level (±SD), determined by radioimmunoassay, was 37.5 ± 24.2 μM (8.4 ± 5.4 μg/ml), twice the level found at this dose in patients with normal renal function (NRF). In the CRF volunteers, significant plasma levels (3.0 ± 1.4 μM) persisted at 47 hours after drug administration (before hemodialysis) whereas in the NRF patients levels dropped to less than 1 μM by 11 hours. Hemodialysis was started 47 hours after infusion and was continued for six hours. The pre-dialysis plasma drug level was reduced by 61.5 percent at 0.25 to 1.5 hours after the end of dialysis. The mean plasma t 1 2 during dialysis of 5.4 hours, the extraction ratio of 0.44, and the dialysis clearance for plasma of 113 ml/min indicate that acyclovir is efficiently removed by hemodialysis. One-half the suggested intravenous dose for a particular indication can be given every 24 hours and a similar replacement dose should be given after each dialysis.

Original languageEnglish (US)
Pages (from-to)202-204
Number of pages3
JournalThe American journal of medicine
Volume73
Issue number1 PART 1
DOIs
StatePublished - Jul 20 1982

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure'. Together they form a unique fingerprint.

  • Cite this

    Krasny, H. C., Liao, S. H. T., Miranda, P. D., Laskin, O. L., Whelton, A., & Lietman, P. S. (1982). Influence of hemodialysis on acyclovir pharmacokinetics in patients with chronic renal failure. The American journal of medicine, 73(1 PART 1), 202-204. https://doi.org/10.1016/0002-9343(82)90091-2